Cencora, Inc. $COR Shares Purchased by Concurrent Investment Advisors LLC

Concurrent Investment Advisors LLC increased its stake in shares of Cencora, Inc. (NYSE:COR) by 69.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 14,259 shares of the company’s stock after purchasing an additional 5,860 shares during the period. Concurrent Investment Advisors LLC’s holdings in Cencora were worth $4,816,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Optima Capital LLC purchased a new position in shares of Cencora during the 4th quarter worth approximately $31,000. IAG Wealth Partners LLC purchased a new position in shares of Cencora during the 3rd quarter worth approximately $30,000. Cloud Capital Management LLC purchased a new position in shares of Cencora during the 3rd quarter worth approximately $31,000. Caitlin John LLC purchased a new position in shares of Cencora during the 3rd quarter worth approximately $31,000. Finally, Harbor Investment Advisory LLC purchased a new position in shares of Cencora during the 4th quarter worth approximately $35,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Evercore set a $360.00 price objective on shares of Cencora in a research report on Wednesday, April 8th. Finally, Wells Fargo & Company increased their price objective on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Twelve research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $398.17.

Cencora Price Performance

Cencora stock opened at $307.60 on Monday. The firm has a market cap of $59.84 billion, a PE ratio of 36.97, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. Cencora, Inc. has a 52-week low of $271.00 and a 52-week high of $377.54. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The company’s 50 day moving average is $337.33 and its two-hundred day moving average is $343.49.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The company had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the business earned $3.73 EPS. On average, research analysts expect that Cencora, Inc. will post 17.57 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Friday, February 13th. Cencora’s dividend payout ratio (DPR) is presently 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.